-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Cullinan Oncology (NASDAQ:CGEM) Shares Gap Up to $12.76
Cullinan Oncology (NASDAQ:CGEM) Shares Gap Up to $12.76
Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) shares gapped up prior to trading on Wednesday . The stock had previously closed at $12.76, but opened at $13.60. Cullinan Oncology shares last traded at $12.84, with a volume of 148 shares.
Cullinan Oncology Stock Down 3.3 %
The company has a market cap of $547.34 million, a PE ratio of 5.40 and a beta of -0.09. The business's fifty day moving average is $12.64 and its 200-day moving average is $12.65.
Get Cullinan Oncology alerts:Insiders Place Their Bets
In other Cullinan Oncology news, insider Jennifer Michaelson sold 4,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 27th. The shares were sold at an average price of $12.40, for a total transaction of $49,600.00. Following the sale, the insider now owns 53,031 shares in the company, valued at approximately $657,584.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.50% of the stock is owned by company insiders.
Institutional Investors Weigh In On Cullinan Oncology
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rock Springs Capital Management LP raised its stake in Cullinan Oncology by 1.0% during the 1st quarter. Rock Springs Capital Management LP now owns 652,578 shares of the company's stock worth $6,832,000 after acquiring an additional 6,500 shares during the period. Dupont Capital Management Corp bought a new stake in Cullinan Oncology during the 1st quarter worth approximately $119,000. Victory Capital Management Inc. bought a new stake in Cullinan Oncology during the 3rd quarter worth approximately $538,000. Nisa Investment Advisors LLC raised its stake in Cullinan Oncology by 24.0% during the 3rd quarter. Nisa Investment Advisors LLC now owns 17,241 shares of the company's stock worth $222,000 after acquiring an additional 3,341 shares during the period. Finally, Silverarc Capital Management LLC raised its position in shares of Cullinan Oncology by 5.4% during the third quarter. Silverarc Capital Management LLC now owns 224,555 shares of the company's stock valued at $2,879,000 after buying an additional 11,465 shares during the last quarter. Institutional investors own 82.53% of the company's stock.Cullinan Oncology Company Profile
(Get Rating)
Cullinan Oncology Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
See Also
- Get a free copy of the StockNews.com research report on Cullinan Oncology (CGEM)
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML's November Rally Have Staying Power?
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ's Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) shares gapped up prior to trading on Wednesday . The stock had previously closed at $12.76, but opened at $13.60. Cullinan Oncology shares last traded at $12.84, with a volume of 148 shares.
库利南肿瘤学公司(纳斯达克代码：CGEM-GET Rating)的股价周三在交易前大幅上涨。该股此前收于12.76美元，但开盘报13.60美元。库利南肿瘤学的股票最新报12.84美元，成交量为148股。
Cullinan Oncology Stock Down 3.3 %
库利南肿瘤学股票下跌3.3%
The company has a market cap of $547.34 million, a PE ratio of 5.40 and a beta of -0.09. The business's fifty day moving average is $12.64 and its 200-day moving average is $12.65.
该公司市值为5.4734亿美元，市盈率为5.40倍，贝塔系数为-0.09。该业务的50日移动均线切入位为12.64美元，200日移动均线切入位为12.65美元。
Insiders Place Their Bets
内部人士下注
In other Cullinan Oncology news, insider Jennifer Michaelson sold 4,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 27th. The shares were sold at an average price of $12.40, for a total transaction of $49,600.00. Following the sale, the insider now owns 53,031 shares in the company, valued at approximately $657,584.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.50% of the stock is owned by company insiders.
在库利南肿瘤学的其他新闻中，内部人士詹妮弗·迈克尔森在9月27日星期二的一笔交易中出售了4000股该公司的股票。这些股票以12.40美元的平均价格出售，总成交额为49,600.00美元。出售后，这位内部人士现在拥有该公司53,031股，价值约657,584.40美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过此超链接。7.50%的股份由公司内部人士持有。
Institutional Investors Weigh In On Cullinan Oncology
机构投资者参与库利南肿瘤学
Cullinan Oncology Company Profile
库利南肿瘤学公司简介
(Get Rating)
(获取评级)
Cullinan Oncology Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
库利南肿瘤公司是一家生物制药公司，专注于为美国的癌症患者开发一系列靶向肿瘤学和免疫肿瘤学疗法。该公司的主要候选药物是CLN-081，这是一种口服小分子药物，正在进行I/IIa期剂量升级和扩大试验，用于治疗非小细胞肺癌患者。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Cullinan Oncology (CGEM)
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML's November Rally Have Staying Power?
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ's Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
- 免费获取StockNews.com关于库利南肿瘤学的研究报告(CGEM)
- Verra移动库存已返回空间站
- ASML的11月拉力赛有后劲吗？
- 在盈利暴跌后，Advance Auto Parts是一笔买入吗？
- BJ‘s批发俱乐部：当心卖方
- 马伦汽车股票的下一个催化剂是12月23日
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接受库利南肿瘤学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对库利南肿瘤学和相关公司的最新新闻和分析师评级的每日简明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧